Our technological environment is changing, and more and more we conduct our daily lives in the cloud...

All of our information is now stored in this nebulous place and is available all the time and anywhere on multiple devices. This has had a profound impact on how we communicate and collaborate. This of course is also having an impact on how we perceive and wish to consume technology within the pharmaceutical industry. However, our industry has been traditionally slow to adopt new technology given the highly regulated nature of our activities. We are now seeing a movement towards cloud based solutions and defining a qualified cloud strategy should really be your first step.

This webinar discusses how companies are moving towards cloud based environments and how they can implement a strategy which will allow them to meet regulatory requirements while gaining the full benefits that cloud can bring. We will cover the following subjects:

        
round-done-button.png

 What is cloud computing and how is it being used in Pharma

round-done-button.png

 What are the regulatory barriers and how can these be overcome

round-done-button.png

 GAMP special interest group on Cloud computing for GxP applications

round-done-button.png

 Individual SaaS solutions or one centralized cloud environment?

round-done-button.png

 Migration strategy for legacy on premise applications

round-done-button.png

 Cloud qualification and management


For information on the other parts of this series visit our webinars section

Your Presenters:

 

paulfenton

Paul Fenton - President & CEO, Montrium

Paul has over a decade of industry experience at a senior management level in the development, deployment and management of computerized systems for use in regulated clinical trials. He co-founded Montrium in 2005. View full bio

michaelzwetkow

Michael Zwetkow - VP Operations, Montrium

Michael Zwetkow has over 15 years industry experience and currently heads up the Operations group at Montrium. He has worked across the globe with some of the larger pharmaceutical companies, as well as numerous medium and smaller sized biotech companies. View full bio